Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Type 2 Diabetes

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

The once-daily small-molecule pill can be taken without empty-stomach restrictions.

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials